Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
8.28 USD | -1.66% | -4.25% | -1.87% |
Financials (USD)
Sales 2024 * | 50.06M | Sales 2025 * | 51.85M | Capitalization | 458M |
---|---|---|---|---|---|
Net income 2024 * | -81M | Net income 2025 * | -98M | EV / Sales 2024 * | 2.09 x |
Net cash position 2024 * | 353M | Net cash position 2025 * | 365M | EV / Sales 2025 * | 1.79 x |
P/E ratio 2024 * |
-5.59
x | P/E ratio 2025 * |
-5.03
x | Employees | 162 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 83.09% |
Latest transcript on Voyager Therapeutics, Inc.
1 day | -0.71% | ||
1 week | +0.24% | ||
Current month | +0.24% | ||
1 month | -0.24% | ||
3 months | -10.14% | ||
6 months | +8.51% | ||
Current year | -0.24% |
Managers | Title | Age | Since |
---|---|---|---|
Alfred Sandrock
CEO | Chief Executive Officer | 67 | 22-02-28 |
Robin Swartz
DFI | Director of Finance/CFO | 53 | 21-08-31 |
Michael Higgins
CHM | Chairman | 61 | 15-07-21 |
Members of the board | Title | Age | Since |
---|---|---|---|
George Scangos
BRD | Director/Board Member | 76 | 23-05-08 |
James Geraghty
BRD | Director/Board Member | 69 | 13-12-31 |
Glenn Pierce
BRD | Director/Board Member | 68 | 17-01-04 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.05% | 2 M€ | -.--% | ||
0.01% | 0 M€ | 0.00% | - | |
0.00% | 32 M€ | +4.30% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-10 | 8.28 | -1.66% | 8 814 |
24-06-07 | 8.42 | -0.71% | 236,345 |
24-06-06 | 8.48 | -2.53% | 336,350 |
24-06-05 | 8.7 | +2.23% | 327,979 |
24-06-04 | 8.51 | -1.62% | 403,049 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-0.24% | 458M | |
+51.85% | 57.87B | |
+42.10% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- VYGR Stock